POLARx and POLARx Cryoablation Balloon Catheters; POLARSHEATH Steerable Sheaths; SMARTFREEZE Cryoablation System Console
BOSTON SCIENTIFIC CORPORATION · Decision date May 29, 2026
What did the FDA approve?
FDA records P220032/S012 as a supplement to PMA P220032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 29, 2026.
FDA approval order statement
Approval to amend the PAS protocol to terminate enrollment, discontinue all protocol-required follow-up beyond the 3-month visit, and conduct an analysis of all available data collected to date
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- May 29, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P220032/S012
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- OAE
- Decision code
- APPR
- Decision date
- May 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Boston Scientific Corporation
- Product code
- OAE
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220032/S011 · Related supplement
POLARx Cryoablation System
P220032/S012 received
Application receipt date recorded by FDA.
P220032/S012 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P220032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
POLARx Cryoablation SystemP220032/S011 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 14, 2025 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P220032/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


